{
    "clinical_study": {
        "@rank": "75528", 
        "arm_group": [
            {
                "arm_group_label": "HSS (3%) + epinephrine", 
                "arm_group_type": "Active Comparator", 
                "description": "Nebulized solution containing  0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of HSS(3%) every 4h for three times and afterwards at physician in charge criteria."
            }, 
            {
                "arm_group_label": "HHHFNC+epinephrine+Normal Saline(0.9%)", 
                "arm_group_type": "Experimental", 
                "description": "Flow depending on weight (Tidal volume x respiratory rate x 9) and nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of Normal Saline (NS) (0.9%) every 4h and afterwards at physician in charge criteria."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate that heated, humidified, high-flow nasal cannula\n      (HHHFNC) is superior to hypertonic saline solution (HSS) in the treatment of moderate acute\n      viral bronchiolitis in infants in improving respiratory distress and comfort and reducing\n      length of hospital stay (LOS) and admission to Pediatric Intensive Care Unit (PICU)."
        }, 
        "brief_title": "High Flow Therapy vs Hypertonic Saline in Bronchiolitis", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Acute Viral Bronchiolitis", 
        "condition_browse": {
            "mesh_term": [
                "Bronchiolitis", 
                "Bronchiolitis, Viral"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children aged 6 months or less\n\n          -  Moderate (Respiratory Distress Assessment Instrument score of 4 or greater) viral\n             bronchiolitis (as defined by McConnockie)\n\n          -  Meeting Admission criteria\n\n        Exclusion Criteria:\n\n          -  History of prematurity\n\n          -  Chronic lung disease\n\n          -  Cystic fibrosis\n\n          -  Congenital heart disease\n\n          -  Neuromuscular disease\n\n          -  Airway anomalies\n\n          -  Immunodeficiency\n\n          -  Those requiring immediate intubation and ventilation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "6 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01873144", 
            "org_study_id": "EC11-437"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HSS (3%) + epinephrine", 
                    "HHHFNC+epinephrine+Normal Saline(0.9%)"
                ], 
                "description": "Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria", 
                "intervention_name": "Epinephrine 1/1000", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Adrenaline 1/1000", 
                    "Adrenalin 1/1000"
                ]
            }, 
            {
                "arm_group_label": "HSS (3%) + epinephrine", 
                "description": "Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria", 
                "intervention_name": "HSS 3%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HHHFNC+epinephrine+Normal Saline(0.9%)", 
                "description": "Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age", 
                "intervention_name": "HHHFNC", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "HHHFNC+epinephrine+Normal Saline(0.9%)", 
                "description": "Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria", 
                "intervention_name": "NS (0.9%)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Normal saline solution 0.9%", 
                    "Physiologic saline solution"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Epinephrine", 
                "Epinephryl borate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bronchiolitis", 
            "Hypertonic saline solution", 
            "High-flow oxygen therapy", 
            "Respiratory distress", 
            "Comfort"
        ], 
        "lastchanged_date": "June 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Alcorcon", 
                        "country": "Spain", 
                        "state": "Madrid", 
                        "zip": "28922"
                    }, 
                    "name": "Hospital Universitario Fundacion Alcorcon"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leganes", 
                        "country": "Spain", 
                        "state": "Madrid", 
                        "zip": "28911"
                    }, 
                    "name": "Hospital Universitario Severo Ochoa"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "High Flow Therapy vs Hypertonic Saline in Bronchiolitis Treatment. Randomized Controlled Trial", 
        "other_outcome": [
            {
                "measure": "Length of hospital stay (LOS) in days in both groups", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 5 days"
            }, 
            {
                "description": "Transfer to PICU criteria were defined.", 
                "measure": "Admission to Pediatric Intensive Care Unit PICU (rate) in both groups", 
                "safety_issue": "No", 
                "time_frame": "Transfer to PICU at any time during hospitalization"
            }
        ], 
        "overall_official": {
            "affiliation": "Department of Pediatrics and Neonatology. Hospital Universitario Fundacion Alcorcon. Madrid. SPAIN", 
            "last_name": "Mercedes Bueno, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "RACS is calculated by combining 2 values: the difference between the Respiratory Distress Assessment Instrument (RDAI) score before and after treatment, plus a value of +1 for each 10% improvement (decrease) in the posttreatment respiratory rate (RR) or a value of  -1 for each 10% worsening (increase) in RR.", 
            "measure": "Difference in mean Respiratory Assessment Change Score (RACS) between groups in every time considered", 
            "safety_issue": "No", 
            "time_frame": "Every 4h for three consecutive times beginning in the moment of inclusion in the study and after every 8h for three consecutive times (average of 36h)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01873144"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ministry of Health, Spain", 
            "investigator_full_name": "M\u00aaMercedes Bueno Campa\u00f1a", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "A scale was used for comfort evaluation . It is based on 4 items: rest, feeding, alertness and facial expression (facial pictures).Minimum 4-Maximum 16", 
            "measure": "Difference in mean comfort score along the monitoring period between groups", 
            "safety_issue": "No", 
            "time_frame": "Every 8h for 6  consecutive times (two days) beginning in the moment of inclusion in the study"
        }, 
        "source": "Ministry of Health, Spain", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ministry of Health, Spain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}